Pure Global AI
NCT06334458Recruitment Completed

Epigenomic and Machine Learning Models to Predict Pancreatic Cancer

Development of a New Algorithm to Integrate Clinical, Omics, DNA Methylation Biomarkers and Epidemiological Data for Early Detection of Pancreatic Cancer in High-risk Individuals
European Institute of OncologyClinicalTrials.govdiagnostic test
Verified
Study focus
Disease/Condition
Pancreatic Cancer
Drug/Device/Intervention
Early diagnosis for Pancreatic Cancers in high-risk asymptomatic subject groups
Study type
Interventional
Intervention type
diagnostic test
Sponsor & location
Primary sponsor
European Institute of Oncology
Location
Toulouse,Milan,Cluj-Napoca,Barcelona, France,Italy,Romania,Spain
Timeline & enrollment
Phase
N/A
Start date
Feb 03, 2023
End date
Dec 31, 2024
Enrollment
170 participants
Primary outcome

Observation of a two or three-fold enrichment in early detection of suspicious pancreatic lesion using the CRPA algorithm,Identification of one or more abnormal methylation changes present in blood cells of participants with suspicious lesions versus methylation profiles of participants with no identified lesions,Validation of igenetic biomarker testing in liquid biopsy followed by radiological exam as early cancer diagnostic tool

Summary

The goal of the multicentric and interdisciplinary IMAGene project is to pursue early
 diagnosis for Pancreatic Cancers in high-risk asymptomatic subject groups, by developing and
 validating a comprehensive cancer risk prediction algorithm (CRPA) as a clinical support tool
 to calculate a personalized risk profile.
 
 The study is a longitudinal, non-randomized exploratory clinical study. A total of 170
 asymptomatic first-degree relatives of PC patients.

ICD-10 classifications
Malignant neoplasm of pancreasMalignant neoplasm: Pancreas, unspecifiedMalignant neoplasm: Head of pancreasMalignant neoplasm: Tail of pancreasMalignant neoplasm: Other parts of pancreas
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06334458
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06334458 through Pure Global AI's free database. This phase not specified trial is sponsored by European Institute of Oncology and is currently Recruitment Completed. The study focuses on Pancreatic Cancer. Target enrollment is 170 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.